- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD). As quoted in the press release: AXS-05 …
Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD).
As quoted in the press release:
AXS-05 is a novel, oral, investigational medicine, consisting of dextromethorphan and bupropion, with glutamatergic, monoaminergic, and anti-inflammatory mechanisms. Topline results from the ASCEND trial are expected early January 2019.
“We are excited to complete enrollment of the ASCEND trial, and we look forward to the upcoming results of this study. ASCEND is evaluating the effect of AXS-05 as compared to bupropion on the symptoms of major depressive disorder,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We believe that the multiple mechanisms of action of AXS-05 may be relevant to other CNS disorders. In addition to major depressive disorder, we are also evaluating AXS-05 in treatment resistant depression with the ongoing STRIDE-1 Phase 3 trial, agitation associated with Alzheimer’s disease with the ongoing ADVANCE-1 Phase 2/3 trial, and smoking cessation with a Phase 2 trial that is being conducted under a research collaboration with Duke University.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â